🔬 New insights: T-DM1 remains a justified switch for HER2-negative residual breast cancer after neoadjuvant therapy! 🚀
In a recent publication in the Journal 'The Breast', new findings from the KATHERINE study show that patients with HER2-positive breast cancer who were documented to have HER2-negative residual disease after neoadjuvant therapy still derive significant benefit from adjuvant T-DM1 therapy.
These results challenge the assumption that biomarker changes in residual disease accurately reflect the biology of micrometastatic disease. Despite a transition to HER2-negative status, patients treated with T-DM1 experienced a significant improvement in invasive disease-free survival (iDFS) compared to trastuzumab (95.2% vs. 60.3%).
The data supports continued use of T-DM1, even in the event of HER2-negative transition, and suggests that re-assessing HER2 status after therapy could be misleading and may potentially lead to the failure to administer an effective therapy to a high-risk patient group.
Read the full publication here.
